Compare WK & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WK | IOVA |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 968.6M |
| IPO Year | 2014 | N/A |
| Metric | WK | IOVA |
|---|---|---|
| Price | $87.45 | $2.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $104.50 | $10.36 |
| AVG Volume (30 Days) | 597.7K | ★ 9.8M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $845,522,000.00 | $250,425,000.00 |
| Revenue This Year | $22.69 | $60.94 |
| Revenue Next Year | $15.85 | $60.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 19.86 | ★ 175.62 |
| 52 Week Low | $60.50 | $1.64 |
| 52 Week High | $116.83 | $8.56 |
| Indicator | WK | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 46.56 |
| Support Level | $89.69 | $2.18 |
| Resistance Level | $93.71 | $2.32 |
| Average True Range (ATR) | 2.56 | 0.12 |
| MACD | -0.69 | -0.01 |
| Stochastic Oscillator | 29.15 | 18.11 |
Workiva Inc is a cloud-native platform that simplifies the complexities of reporting and compliance. Workiva platform empowers customers by connecting and transforming data from hundreds of enterprise resource planning (ERP), human capital management (HCM), and customer relationship management (CRM) systems, as well as other third-party cloud and on-premise applications. Customers use the platform to create, review and publish data-linked documents and reports with greater control, consistency, accuracy, and productivity and it is also used for SEC Filings. Company's Geographical region consist of USA, Netherland, UK, and Others. Majority of revenue is from USA.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.